Key Points
- COO Eric Devroe purchased 10,000 shares on January 13 at an average price of $1.72, raising his stake to 75,308 shares — a 15.31% increase valued around $129,530.
- Acrivon stock opened at $1.87 (12‑month range $1.05–$8.00) with a market cap of about $59.0M; the company reported Q3 EPS of ($0.47), beating estimates by $0.10, while analysts forecast a -2.49 EPS for the current year.
- Wall Street sentiment is mixed but tilted positive with an average “Moderate Buy” rating and a $11.67 target; institutional ownership is high (71.62%) with large inflows from the likes of UBS and Two Sigma and some recent divergent analyst actions (Piper Sandler raised its target, while a few firms issued sell ratings).
Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) COO Eric Devroe acquired 10,000 shares of the business's stock in a transaction that occurred on Tuesday, January 13th. The shares were bought at an average price of $1.72 per share, with a total value of $17,200.00. Following the completion of the purchase, the chief operating officer owned 75,308 shares in the company, valued at $129,529.76. This trade represents a 15.31% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Acrivon Therapeutics Trading Up 2.2%
Acrivon Therapeutics stock opened at $1.87 on Friday. Acrivon Therapeutics, Inc. has a 12-month low of $1.05 and a 12-month high of $8.00. The firm has a market capitalization of $59.02 million, a price-to-earnings ratio of -0.88 and a beta of 1.73. The firm has a 50 day moving average of $2.30 and a 200 day moving average of $1.82.
Acrivon Therapeutics (NASDAQ:ACRV - Get Free Report) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($0.47) earnings per share for the quarter, topping analysts' consensus estimates of ($0.57) by $0.10. On average, analysts predict that Acrivon Therapeutics, Inc. will post -2.49 EPS for the current year.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in ACRV. UBS Group AG increased its position in shares of Acrivon Therapeutics by 150,057.8% during the third quarter. UBS Group AG now owns 683,218 shares of the company's stock worth $1,237,000 after acquiring an additional 682,763 shares during the period. Two Sigma Investments LP lifted its holdings in shares of Acrivon Therapeutics by 76.2% in the 3rd quarter. Two Sigma Investments LP now owns 319,205 shares of the company's stock worth $578,000 after buying an additional 138,033 shares during the period. Jane Street Group LLC bought a new position in shares of Acrivon Therapeutics during the 2nd quarter worth $371,000. XTX Topco Ltd purchased a new stake in Acrivon Therapeutics in the second quarter worth about $126,000. Finally, Algert Global LLC bought a new stake in shares of Acrivon Therapeutics in the 3rd quarter valued at about $81,000. 71.62% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
A number of research analysts have recently weighed in on ACRV shares. HC Wainwright restated a "buy" rating and set a $19.00 price objective on shares of Acrivon Therapeutics in a research report on Tuesday, November 25th. Piper Sandler upped their price objective on Acrivon Therapeutics from $6.00 to $8.00 and gave the stock an "overweight" rating in a report on Friday, January 9th. Wall Street Zen downgraded shares of Acrivon Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, January 10th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Acrivon Therapeutics in a research report on Monday, December 29th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $11.67.
View Our Latest Report on ACRV
Acrivon Therapeutics Company Profile
(
Get Free Report)
Acrivon Therapeutics (NASDAQ:ACRV) is a clinical-stage biotechnology company focused on the discovery and development of stapled peptide therapeutics for the treatment of RAS-driven cancers. Its proprietary platform is designed to enhance the stability, cell permeability and target specificity of peptide molecules, enabling the disruption of protein–protein interactions that are traditionally challenging to inhibit with small-molecule drugs or biologics.
The company's lead development candidate is a hydrocarbon-stapled peptide selectively targeting the KRAS G12C mutation, currently in early clinical trials.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
